Histone Deacetylase Inhibitors Promote the Tumoricidal Effect of HAMLETBREST, Patrick; GUSTAFSSON, Mattias; MOSSBERG, Ann-Kristin et al.Cancer research (Baltimore). 2007, Vol 67, Num 23, pp 11327-11334, issn 0008-5472, 8 p.Article

Histone deacetylase inhibitors in the treatment for multiple myeloma : PIH: Basic and Clinical Updates in Multiple MyelomaHIDESHIMA, Teru; ANDERSON, Kenneth C.International journal of hematology. 2013, Vol 97, Num 3, pp 324-332, issn 0925-5710, 9 p.Article

HDAC inhibitor-based therapies and haematological malignancySTIMSON, L; WOOD, V; KHAN, O et al.Annals of oncology. 2009, Vol 20, Num 8, pp 1293-1302, issn 0923-7534, 10 p.Article

FK228 (depsipeptide) : a HDAC inhibitor with pleiotropic antitumor activitiesKONSTANTINOPOULOS, Panagiotis A; VANDOROS, Gerasimos P; PAPAVASSILIOU, Athanasios G et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 5, pp 711-715, issn 0344-5704, 5 p.Article

Sirtuin ModulatorsMAHAJAN, Sumit S; LEKO, Vid; SIMON, Julian A et al.Handbook of experimental pharmacology. 2011, Vol 206, pp 241-255, issn 0171-2004, 15 p.Article

Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781BANUELOS, Carmen A; BANATH, Judit P; MACPHAIL, Susan H et al.Clinical cancer research. 2007, Vol 13, Num 22, pp 6816-6826, issn 1078-0432, 11 p., 1Article

A mechanism-based potent sirtuin inhibitor containing N-thiocarbamoyl-lysine (TuAcK)HIRSCH, Brett M; YUJUN HAO; XIAOPENG LI et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 16, pp 4753-4757, issn 0960-894X, 5 p.Article

A Novel Agent with Histone Deacetylase Inhibitory Activity Attenuates Neointimal HyperplasiaRAHMATZADEH, M; LIU, H. B; KRISHNA, S. M et al.Cardiovascular drugs and therapy. 2014, Vol 28, Num 5, pp 395-406, issn 0920-3206, 12 p.Article

A novel series of L-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: Design, synthesis and molecular modeling studyDAWEI HUANG; XIAOHUI LI; YINGDONG WEI et al.European journal of medicinal chemistry. 2012, Vol 52, pp 111-122, issn 0223-5234, 12 p.Article

Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanismKWAI FUNG HUI; CHIANG, Alan K. S.International journal of cancer (Print). 2014, Vol 135, Num 12, pp 2950-2961, issn 0020-7136, 12 p.Article

A histone deacetylase-dependent screen in yeastWEERASINGHE, Sujith V. W; WAMBUA, Magdalene; PFLUM, Mary Kay H et al.Bioorganic & medicinal chemistry. 2010, Vol 18, Num 21, pp 7586-7592, issn 0968-0896, 7 p.Article

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitorsPENG GUAN; FENG'E SUN; XUBEN HOU et al.Bioorganic & medicinal chemistry. 2012, Vol 20, Num 12, pp 3865-3872, issn 0968-0896, 8 p.Article

A simple and sensitive high-performance liquid chromatographic method for quantification of PXD101, a histone deacetylase inhibitor in human plasmaNINGNING ZHANG; BOON CHER GOH; YOK MOI KHOO et al.Therapeutic drug monitoring. 2007, Vol 29, Num 2, pp 231-235, issn 0163-4356, 5 p.Article

Towards Histone Deacetylase Inhibitors as New Antimalarial DrugsANDREWS, Katherine T; TRAN, Thanh N; FAIRLIE, David P et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 24, pp 3467-3479, issn 1381-6128, 13 p.Article

Class II histone deacetylases are associated with VHL-lndependent regulation of hypoxia-inducible factor 1αQIAN, David Z; KACHHAP, Sushant K; COLLIS, Spencer J et al.Cancer research (Baltimore). 2006, Vol 66, Num 17, pp 8814-8821, issn 0008-5472, 8 p.Article

Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors : Histone Deacetylase InhibitorsBUTLER, Kyle V; KOZIKOWSKI, Alan P.Current pharmaceutical design. 2008, Vol 14, Num 6, pp 505-528, issn 1381-6128, 24 p.Article

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβMARCHION, Douglas C; BICAKU, Elona; TURNER, Joel G et al.Clinical cancer research. 2005, Vol 11, Num 23, pp 8467-8475, issn 1078-0432, 9 p.Article

Identification of type-specific anticancer histone deacetylase inhibitors: road to successNOUREEN, Nighat; RASHID, Hamid; KALSOOM, Saima et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 4, pp 625-633, issn 0344-5704, 9 p.Article

Histone Deacetylase Inhibitor Enhances Recovery after AKICIANCIOLO COSENTINO, Chiara; SKRYPNYK, Nataliya I; DAVIDSON, Alan J et al.Journal of the American Society of Nephrology. 2013, Vol 24, Num 6, pp 943-953, issn 1046-6673, 11 p.Article

Romidepsin for Cutaneous T-cell LymphomaMILES PRINCE, H; DICKINSON, Michael.Clinical cancer research (Print). 2012, Vol 18, Num 13, pp 3509-3515, issn 1078-0432, 7 p.Article

A putative role for histone deacetylase in the differentiation of human erythroid cellsFUJIEDA, Atsushi; KATAYAMA, Naoyuki; NAKAJIMA, Hidenori et al.International journal of oncology. 2005, Vol 27, Num 3, pp 743-748, issn 1019-6439, 6 p.Article

Mechanisms of HDAC inhibitor-induced thrombocytopeniaMATSUOKA, Hideaki; UNAMI, Akira; FUJIMURA, Takao et al.European journal of pharmacology. 2007, Vol 571, Num 2-3, pp 88-96, issn 0014-2999, 9 p.Article

Targeting epigenetic abnormalities with histone deacetylase inhibitorsCONLEY, Barbara A; WRIGHT, John J; KUMMAR, Shivaani et al.Cancer. 2006, Vol 107, Num 4, pp 832-840, issn 0008-543X, 9 p.Article

The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C6 positionSUN EA CHOI; PFLUM, Mary Kay H.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 23, pp 7084-7086, issn 0960-894X, 3 p.Article

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancerXIAOZHONG QIAN; ARA, Gulshan; MILLS, Evan et al.International journal of cancer. 2008, Vol 122, Num 6, pp 1400-1410, issn 0020-7136, 11 p.Article